News
VSTM
9.23
+19.71%
1.52
Verastem Is Maintained at Buy by Jefferies
Dow Jones · 6h ago
Verastem Price Target Raised to $13.00/Share From $11.00 by Jefferies
Dow Jones · 6h ago
Verastem Is Maintained at Outperform by RBC Capital
Dow Jones · 6h ago
Verastem Price Target Raised to $24.00/Share From $18.00 by BTIG
Dow Jones · 6h ago
Verastem Is Maintained at Buy by BTIG
Dow Jones · 6h ago
Verastem Up Nearly 23%, on Pace for Largest Percent Increase Since January 2025 -- Data Talk
Dow Jones · 11h ago
Jefferies Maintains Buy on Verastem, Raises Price Target to $13
Benzinga · 13h ago
RBC Capital Maintains Outperform on Verastem, Raises Price Target to $19
Benzinga · 14h ago
Fastenal To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga · 17h ago
Verastem price target raised to $19 from $14 at RBC Capital
TipRanks · 17h ago
Verastem: A Real Pancreatic Cancer Drug, Arriving Second
Seeking Alpha · 18h ago
Analysts’ Top Healthcare Picks: Praxis Precision Medicines (PRAX), Verastem (VSTM)
TipRanks · 18h ago
Analysts’ Top Healthcare Picks: Verastem (VSTM), Rezolute (RZLT)
TipRanks · 19h ago
BTIG Maintains Buy on Verastem, Raises Price Target to $24
Benzinga · 19h ago
Verastem Announces $234 Million Oncology Financing Transaction
TipRanks · 1d ago
Verastem price target raised to $13 from $11 at Jefferies
TipRanks · 1d ago
Midday Fly By: BofA fined $1.2B by Treasury, Netflix lays off 6% of staff
TipRanks · 1d ago
Verastem Gets a New CEO, $250M, and a Shot at Another Cancer Drug
Barron‘s · 1d ago
Verastem Oncology's Investigational Drug Delivers Encouraging Responses Across Multiple Cancers
Benzinga · 1d ago
Bending Spoons, Liquidia, Verastem And Other Big Stocks Moving Higher On Wednesday
Benzinga · 1d ago
More
Webull provides a variety of real-time VSTM stock news. You can receive the latest news about Verastem through multiple platforms. This information may help you make smarter investment decisions.
About VSTM
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.